Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

[1]  M. Minden,et al.  Lovastatin Induced Control of Blast Cell Growth in an Elderly Patient with Acute Myeloblastic Leukemia , 2001, Leukemia & lymphoma.

[2]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. , 2000, Current opinion in cell biology.

[3]  Wei Wang,et al.  Mevalonate Prevents Lovastatin-Induced Apoptosis in Medulloblastoma Cell Lines , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[4]  S. Sebti,et al.  Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. , 1999, Cancer research.

[5]  C. Rao,et al.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. , 1999, Gastroenterology.

[6]  H. Mo,et al.  Isoprenoid-Mediated Inhibition of Mevalonate Synthesis: Potential Application to Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[7]  M. Michikawa,et al.  Inhibition of Cholesterol Production but Not of Nonsterol Isoprenoid Products Induces Neuronal Cell Death , 1999, Journal of neurochemistry.

[8]  S. Jung,et al.  Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[10]  M. Minden,et al.  Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. , 1999, Blood.

[11]  D. Gómez-Coronado,et al.  Induction of apoptosis in p53-null HL-60 cells by inhibition of lanosterol 14-α demethylase , 1998 .

[12]  A. Vasudevan,et al.  Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. , 1998, The American journal of physiology.

[13]  R. Kratzke,et al.  Lovastatin induces apoptosis in malignant mesothelioma cells. , 1998, American journal of respiratory and critical care medicine.

[14]  G. Melino,et al.  Cholesterol, but not its esters, triggers programmed cell death in human erythroleukemia K562 cells. , 1998, European journal of biochemistry.

[15]  C. Martínez-A,et al.  Dual role of Ras and Rho proteins: At the cutting edge of life and death , 1998, Immunology and cell biology.

[16]  F. Vrtovsnik,et al.  HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture. , 1997, Kidney international.

[17]  Jasmine Chen,et al.  The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Matzno,et al.  Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. , 1997, Journal of lipid research.

[19]  J. Lacal.  Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid‐dependent signaling , 1997, FEBS letters.

[20]  G R Cunningham,et al.  Lovastatin-induced apoptosis in prostate stromal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  R. Bravo,et al.  Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.

[22]  S. Sebti,et al.  Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity , 1997, Oncogene.

[23]  S. Hakomori.  Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.

[24]  M. Seabra,et al.  Geranylgeranylation of Rab proteins. , 1996, Biochemical Society transactions.

[25]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  H. Yeger,et al.  HMG–CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P–glycoprotein–expressing cells , 1996, Nature Medicine.

[27]  K. Kaibuchi,et al.  Identification of a Putative Target for Rho as the Serine-Threonine Kinase Protein Kinase N , 1996, Science.

[28]  M. Karin,et al.  Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.

[29]  R. Danesi,et al.  Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. , 1995, Biochemical and biophysical research communications.

[30]  J. Ericsson,et al.  Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. , 1994, Biochimica et biophysica acta.

[31]  K. Fujisawa,et al.  ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. , 1993, The Journal of biological chemistry.

[32]  D. Russell,et al.  Bile acid biosynthesis. , 1992, Biochemistry.

[33]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[34]  R. Stocker,et al.  Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[36]  B. Kabakoff,et al.  Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. , 1990, Archives of biochemistry and biophysics.

[37]  L. Penn,et al.  Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  P. Edwards,et al.  Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. , 1999, Annual review of biochemistry.

[39]  C. Reutelingsperger,et al.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. , 1998, Cytometry.

[40]  D. Gómez-Coronado,et al.  Induction of apoptosis in p53-null HL-60 cells by inhibition of lanosterol 14-alpha demethylase. , 1998, Biochimie.

[41]  P. Edwards,et al.  Signaling molecules derived from the cholesterol biosynthetic pathway. , 1997, Sub-cellular biochemistry.

[42]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[43]  G. Bokoch.  Biology of the Rap proteins, members of the ras superfamily of GTP-binding proteins. , 1993, The Biochemical journal.

[44]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[45]  R. Olson,et al.  Biosynthesis of ubiquinone. , 1983, Vitamins and hormones.